Overview Financials News + Filings Key Docs Ownership
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
|
MESOBLAST LTD (MESO)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
04/29/2021 |
GN
| Appendix 4C Quarterly Activity Report |
04/29/2021 |
GN
| Remestemcel-L Reduces Mortality in Patients Less Than 65 Years Old With Moderate/Severe COVID-19 ARDS: Topline 60-Day Results From Randomized Controlled Trial |
04/29/2021 |
GN
| Mesoblast Corporate Update |
03/30/2021 |
GN
| Mesoblast Operational Highlights and Upcoming Milestones |
03/08/2021 |
GN
| Mesoblast Closes US$110/A$138 Million Financing Led by US Strategic Investor Group |
02/10/2021 |
GN
| Mesoblast Phase 3 Trial Shows That a Single Injection of Rexlemestrocel-L + Hyaluronic Acid Carrier Results in at Least Two Years of Pain Reduction With Opioid Sparing Activity in Patients With Chronic Low Back Pain Due to Degenerative Disc Disease |
02/10/2021 |
GN
| Mesoblast Corporate Update |
01/28/2021 |
GN
| Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020 |
01/11/2021 |
GN
| Mesoblast Presents Heart Failure Phase 3 Trial Results at Investor Healthcare Conference |
01/10/2021 |
GN
| Single Dose of Rexlemestrocel-L Provides Substantial and Durable Reduction in Heart Attacks, Strokes and Cardiac Death in Patients With Chronic Heart Failure |
12/14/2020 |
GN
| Mesoblast Provides Topline Results From Phase 3 Trial of Rexlemestrocel-L for Advanced Chronic Heart Failure |
12/14/2020 |
GN
| Mesoblast Corporate Update |
12/07/2020 |
GN
| MESO Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Mesoblast Limited Investors of Class Action and Lead Plaintiff Deadline: December 7, 2020 |
12/07/2020 |
GN
| Remestemcel-L Reduces Inflammatory Biomarkers Predictive of High Mortality in Acute Graft Versus Host Disease |
12/03/2020 |
GN
| MESO FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Reminds Mesoblast Limited Investors of Important December 7 Deadline in Securities Class Action – MESO |
12/02/2020 |
GN
| FDA Grants Fast Track Designation for Remestemcel-L in the Treatment of Acute Respiratory Distress Syndrome Due to COVID-19 |
12/01/2020 |
GN
| DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Mesoblast Limited and Encourages Investors to Contact the Firm |
12/01/2020 |
GN
| DEADLINE ALERT for MESO and RCL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders |
12/01/2020 |
GN
| PGEN, MESO & LOOP Upcoming Deadlines: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm |
11/30/2020 |
GN
| DEADLINE ALERT for RCL, MESO, LOOP, TRQ: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders |
11/25/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mesoblast Limited of Class Action Law Suit and Upcoming Deadline – MESO |
11/25/2020 |
GN
| PGEN, MESO & LOOP Class Actions: Bronstein, Gewirtz & Grossman LLC Reminds Investors of Class Actions and Encourages Investors to Contact the Firm |
11/24/2020 |
GN
| ROSEN, TRUSTED INVESTOR COUNSEL, Reminds Mesoblast Limited Investors of Important December 7 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – MESO |
11/24/2020 |
GN
| DEADLINE ALERT for MESO and RCL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders |
11/23/2020 |
GN
| Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mesoblast Limited (MESO) |
11/22/2020 |
GN
| SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Mesoblast Limited of Class Action Lawsuit and Upcoming Deadline – MESO |
11/19/2020 |
GN
| Operational and Financial Results for the Period Ended September 30, 2020 |
11/19/2020 |
GN
| ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Reminds Mesoblast Limited Investors of Important Deadline in Securities Class Action – MESO |
11/19/2020 |
GN
| Mesoblast Enters Global Collaboration for Development, Manufacture and Commercialization of Remestemcel-L |
11/19/2020 |
GN
| Mesoblast Corporate Update and Financial Results Webcast |
11/18/2020 |
GN
| Mesoblast Limited Investors: Last Days to Participate Actively in the Class Action Lawsuit: Portnoy Law Firm |
11/18/2020 |
GN
| Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Precigen, Royal Caribbean, Mesoblast, and Loop Industries and Encourages Investors to Contact the Firm |
11/18/2020 |
GN
| DEADLINE ALERT for RCL, MESO, LOOP, TRQ: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders |
11/17/2020 |
GN
| DEADLINE ALERT for MESO and RCL: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders |
|
|
|